xCellSense® profiles primary ALL samples including Ph-negative, Ph-positive, and T-ALL to aid in understanding relapse, resistance, and developing targeted therapies.
Request a Quote
ALL spans biologically distinct subtypes (Ph-negative, Ph-positive, T-ALL) with different therapeutic vulnerabilities, and relapse/resistance remains the central clinical problem. Functional data clarifies how an asset performs across these subtypes and disease states.
1
Subtype-resolved sensitivity
Ex vivo drug sensitivity testing for your asset and the standard panel across Ph-negative, Ph-positive, and T-ALL
2
Relapse vs. diagnosis
Comparative response in samples taken at diagnosis and at relapse
3
Combination screening
Asset ± backbone agents with synergy quantification
4
Biomarker correlation
Genotype/phenotype-to-response association for enrichment hypotheses
Subtype-aware patient selection, differentiation of relapse/resistance, and stronger inclusion criteria for ALL trials.
Key Deliverables
A scientist will scope a tailored AML study and return a design and timeline.
